XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.
about
Pharmacotherapies for obesity: past, current, and future therapies2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary].Metformin and body weightLong-term drug treatment for obesity: a systematic and clinical reviewLong-term effects of weight-reducing drugs in people with hypertensionLong-term effects of weight-reducing drugs in hypertensive patientsLong-term effects of weight-reducing drugs in hypertensive patientsLong-term pharmacotherapy for obesity and overweightAnti-Obesity Drugs: A Review about Their Effects and SafetyRegulatory challenges for new drugs to treat obesity and comorbid metabolic disordersPrevalence, predisposition and prevention of type II diabetes.Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?Through Thick and Thin: Identifying Barriers to Bariatric Surgery, Weight Loss Maintenance, and Tailoring Obesity Treatment for the FutureDiabetes DyslipidemiaLong-term weight loss maintenance for obesity: a multidisciplinary approachThe GLP-1 agonist, liraglutide, as a pharmacotherapy for obesityThe metabolic vascular syndrome - guide to an individualized treatmentWeight management in obesity - past and presentTreating morbid obesity in cirrhosis: A quest of holy grailTreatment of prediabetesAdvances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors' Expert ForumTherapeutic Use of Metformin in Prediabetes and Diabetes PreventionThe New Era of Drug Therapy for Obesity: The Evidence and the ExpectationsObesity pharmacotherapy: current perspectives and future directionsIndependent and combined effect of diet and exercise in adults with prediabetesInterventions to preserve beta-cell function in the management and prevention of type 2 diabetesAdipokines - removing road blocks to obesity and diabetes therapyDoes orlistat cause acute kidney injury?Can medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery?Challenging obesity: Patient, provider, and expert perspectives on the roles of available and emerging nonsurgical therapies.Current and emerging medications for overweight or obesity in people with comorbiditiesEfficacy comparison of medications approved for chronic weight managementNext generation of weight management medications: implications for diabetes and CVD riskAntiobesity pharmacotherapy for patients with type 2 diabetes: focus on long-term managementOperon for biosynthesis of lipstatin, the Beta-lactone inhibitor of human pancreatic lipaseEffect of anti-obesity drug on cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trialsTreating type 2 diabetes mellitus with traditional chinese and Indian medicinal herbsObesity: Current and potential pharmacotherapeutics and targets.Rats' urinary metabolomes reveal the potential roles of functional foods and exercise in obesity management.Optimal Pharmacologic Treatment Strategies in Obesity and Type 2 Diabetes
P2860
Q21296814-C9B4E084-0D36-42CD-AD24-9CC7A006B6E8Q22241393-7556EFD5-614B-4BA5-99B4-AF9B7D47DF3AQ22250988-45C4E18C-B02D-4B59-B4D3-449E30CFF1DFQ22253010-E99E80B0-1B54-41C7-9E2C-87C7C647D6DDQ24186054-D504EF69-336F-4698-822D-BDEE5C5BE11BQ24200212-FD7555F4-F17C-4CF9-B987-52597AFD3DA6Q24239850-B2319AF1-A1DD-463F-A824-AF69F65CFC88Q24247723-17F28D0B-7928-4390-A4EA-A20D85A6C88EQ24630947-3D8DA2D2-C753-4167-9363-D2D080B1869DQ24658031-56C45DC7-69A5-4AE9-938E-B7BC4084EA34Q24815863-0AD89BE8-9D06-4148-B7B9-A424C68A710BQ26740253-5AF0A55C-E3ED-4BE2-82ED-CEF7EC229851Q26744521-5354B6BF-D5C9-40A7-8CF6-49E72F193C7FQ26750905-7393EBCB-F810-4911-B6DE-736B9B2C2AB8Q26751241-AD5E0002-9275-480E-A695-2F1F1FD351C2Q26765609-FBD11F7B-4CAD-4050-9B9A-60C75341CDE6Q26767142-27336FBD-69B6-4AA9-A92C-99C457C9BB4BQ26774747-92D6DD3D-9661-4AD3-81F2-948C2BEC479AQ26775811-CB2CE73E-F839-489F-93ED-DFE1E8C05866Q26783350-39A4BFAE-9118-4FE1-A4FA-B041351898B8Q26784022-EB617D17-48AA-436F-B831-7B7F05FD1F84Q26822066-EE411B37-1C48-4BD9-A99D-12D255EE18D2Q26827555-B4740F97-2578-49DA-8119-E5DA63BCA1F7Q26828559-7434CF82-8F6D-441F-9983-471927C3068AQ26828591-B0EC9D7A-C1B7-4AB6-9961-E50ECC3846AEQ26830871-9AE5A8B6-11D3-4660-8003-27A572BE1095Q26995825-31C7AD09-870B-42B0-ADF5-8A49F271FC58Q26996838-E90D5836-2605-4568-98BA-F6BC9A102785Q27015789-F6075DB5-1963-49D3-80DF-7EB1EA86E451Q27331844-23208017-A406-4030-8835-20482E16C738Q28080825-A2FAE05E-8896-46C8-9893-6EDDE1B8D203Q28081944-CFD4FBC9-E09C-4887-8B1A-72E246EFD324Q28082858-9C1718D6-2517-44B0-977C-571B3B514E23Q28084337-D011B5C0-825D-40A8-9396-C6482B33F3A0Q28248341-6FDA8618-BCD6-403C-BDAD-5834A2689F46Q28480564-958AAC65-2614-4B13-9EFB-2B9D12EF194AQ28687165-1617B5FF-FC6A-4930-ADFB-458C06ECD738Q30243992-215E7870-C0D8-4CD7-9CD0-0AF138BCE3BBQ30313428-71795B67-6490-4ACF-A7EF-676878B9809DQ30377441-A27FD843-F7D9-4657-A477-CA30F19EFCCA
P2860
XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
XENical in the prevention of d ...... 2 diabetes in obese patients.
@ast
XENical in the prevention of d ...... 2 diabetes in obese patients.
@en
type
label
XENical in the prevention of d ...... 2 diabetes in obese patients.
@ast
XENical in the prevention of d ...... 2 diabetes in obese patients.
@en
prefLabel
XENical in the prevention of d ...... 2 diabetes in obese patients.
@ast
XENical in the prevention of d ...... 2 diabetes in obese patients.
@en
P2093
P921
P356
P1433
P1476
XENical in the prevention of d ...... 2 diabetes in obese patients.
@en
P2093
Jarl S Torgerson
Jonathan Hauptman
Lars Sjöström
Mark N Boldrin
P304
P356
10.2337/DIACARE.27.1.155
P407
P577
2004-01-01T00:00:00Z